STRESSEconomicGlobal
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Published:
News summary
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
- Importance
- Low · 24/100
- Impact direction
- Uncertain